Insulinoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
| Line 18: | Line 18: | ||
*An oral mTOR inhibitor, [[Everolimus]], make better [[Glycemic control|glycemic contro]]<nowiki/>l in people having an insulinoma.<ref name="pmid19129539">{{cite journal| author=Kulke MH, Bergsland EK, Yao JC| title=Glycemic control in patients with insulinoma treated with everolimus. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 2 | pages= 195-7 | pmid=19129539 | doi=10.1056/NEJMc0806740 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19129539 }} </ref> The pathway will give more possibilities for medical treatment. <ref name="pmid22711648">{{cite journal| author=Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L et al.| title=Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. | journal=J Surg Oncol | year= 2012 | volume= 106 | issue= 8 | pages= 972-80 | pmid=22711648 | doi=10.1002/jso.23176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711648 }} </ref> | *An oral mTOR inhibitor, [[Everolimus]], make better [[Glycemic control|glycemic contro]]<nowiki/>l in people having an insulinoma.<ref name="pmid19129539">{{cite journal| author=Kulke MH, Bergsland EK, Yao JC| title=Glycemic control in patients with insulinoma treated with everolimus. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 2 | pages= 195-7 | pmid=19129539 | doi=10.1056/NEJMc0806740 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19129539 }} </ref> The pathway will give more possibilities for medical treatment. <ref name="pmid22711648">{{cite journal| author=Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L et al.| title=Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. | journal=J Surg Oncol | year= 2012 | volume= 106 | issue= 8 | pages= 972-80 | pmid=22711648 | doi=10.1002/jso.23176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711648 }} </ref> | ||
*[[Mitochondria]] play a key role in [[glucose]] and [[insulin]] coupling to assure [[insulin]] [[secretion]] after [[glucose]] stimulation in pancreatic β cells. Coupling is impaired due to abnormal [[mitochondrial]] function in β cells causes the death of the cell.<ref name="pmid22766318">{{cite journal| author=Supale S, Li N, Brun T, Maechler P| title=Mitochondrial dysfunction in pancreatic β cells. | journal=Trends Endocrinol Metab | year= 2012 | volume= 23 | issue= 9 | pages= 477-87 | pmid=22766318 | doi=10.1016/j.tem.2012.06.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22766318 }} </ref> [[YY1]] regulates this [[mitochondrial]] function.<ref name="pmid18046414">{{cite journal| author=Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P| title=mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. | journal=Nature | year= 2007 | volume= 450 | issue= 7170 | pages= 736-40 | pmid=18046414 | doi=10.1038/nature06322 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18046414 }} </ref> T372R mutation increases the [[transcription]] of YY1.<ref name="CaoGao2013">{{cite journal|last1=Cao|first1=Yanan|last2=Gao|first2=Zhibo|last3=Li|first3=Lin|last4=Jiang|first4=Xiuli|last5=Shan|first5=Aijing|last6=Cai|first6=Jie|last7=Peng|first7=Ying|last8=Li|first8=Yanli|last9=Jiang|first9=Xiaohua|last10=Huang|first10=Xuanlin|last11=Wang|first11=Jiaqian|last12=Wei|first12=Qing|last13=Qin|first13=Guijun|last14=Zhao|first14=Jiajun|last15=Jin|first15=Xiaolong|last16=Liu|first16=Li|last17=Li|first17=Yingrui|last18=Wang|first18=Weiqing|last19=Wang|first19=Jun|last20=Ning|first20=Guang|title=Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1|journal=Nature Communications|volume=4|year=2013|issn=2041-1723|doi=10.1038/ncomms3810}}</ref> | *[[Mitochondria]] play a key role in [[glucose]] and [[insulin]] coupling to assure [[insulin]] [[secretion]] after [[glucose]] stimulation in pancreatic β cells. Coupling is impaired due to abnormal [[mitochondrial]] function in β cells causes the death of the cell.<ref name="pmid22766318">{{cite journal| author=Supale S, Li N, Brun T, Maechler P| title=Mitochondrial dysfunction in pancreatic β cells. | journal=Trends Endocrinol Metab | year= 2012 | volume= 23 | issue= 9 | pages= 477-87 | pmid=22766318 | doi=10.1016/j.tem.2012.06.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22766318 }} </ref> [[YY1]] regulates this [[mitochondrial]] function.<ref name="pmid18046414">{{cite journal| author=Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P| title=mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. | journal=Nature | year= 2007 | volume= 450 | issue= 7170 | pages= 736-40 | pmid=18046414 | doi=10.1038/nature06322 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18046414 }} </ref> | ||
*T372R mutation increases the [[transcription]] of YY1.<ref name="CaoGao2013">{{cite journal|last1=Cao|first1=Yanan|last2=Gao|first2=Zhibo|last3=Li|first3=Lin|last4=Jiang|first4=Xiuli|last5=Shan|first5=Aijing|last6=Cai|first6=Jie|last7=Peng|first7=Ying|last8=Li|first8=Yanli|last9=Jiang|first9=Xiaohua|last10=Huang|first10=Xuanlin|last11=Wang|first11=Jiaqian|last12=Wei|first12=Qing|last13=Qin|first13=Guijun|last14=Zhao|first14=Jiajun|last15=Jin|first15=Xiaolong|last16=Liu|first16=Li|last17=Li|first17=Yingrui|last18=Wang|first18=Weiqing|last19=Wang|first19=Jun|last20=Ning|first20=Guang|title=Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1|journal=Nature Communications|volume=4|year=2013|issn=2041-1723|doi=10.1038/ncomms3810}}</ref> | |||
*The understanding of role and functions of [[YY1]] in β cells in near future might prove to be therapeutic potentials. | *The understanding of role and functions of [[YY1]] in [[Beta cells|β cells]] in near future might prove to be therapeutic potentials. | ||
*The progression to [[hypoglycemia]] is actually because of decreased [[glucose]] synthesis rather than increased use due to the direct effect of [[insulin]] on the [[liver]].<ref name="RizzaHaymond1981">{{cite journal|last1=Rizza|first1=R. A.|last2=Haymond|first2=M. W.|last3=Verdonk|first3=C. A.|last4=Mandarino|first4=L. J.|last5=Miles|first5=J. M.|last6=Service|first6=F. J.|last7=Gerich|first7=J. E.|title=Pathogenesis of Hypoglycemia in Insulinoma Patients: Suppression of Hepatic Glucose Production by Insulin|journal=Diabetes|volume=30|issue=5|year=1981|pages=377–381|issn=0012-1797|doi=10.2337/diab.30.5.377}}</ref> | *The progression to [[hypoglycemia]] is actually because of decreased [[glucose]] synthesis rather than increased use due to the direct effect of [[insulin]] on the [[liver]].<ref name="RizzaHaymond1981">{{cite journal|last1=Rizza|first1=R. A.|last2=Haymond|first2=M. W.|last3=Verdonk|first3=C. A.|last4=Mandarino|first4=L. J.|last5=Miles|first5=J. M.|last6=Service|first6=F. J.|last7=Gerich|first7=J. E.|title=Pathogenesis of Hypoglycemia in Insulinoma Patients: Suppression of Hepatic Glucose Production by Insulin|journal=Diabetes|volume=30|issue=5|year=1981|pages=377–381|issn=0012-1797|doi=10.2337/diab.30.5.377}}</ref> | ||
| Line 27: | Line 28: | ||
==Genetics== | ==Genetics== | ||
*Insulinoma is transmitted in an [[autosomal dominant]] pattern when it is associated with [[MEN 1 syndrome]]. | *Insulinoma is transmitted in an [[autosomal dominant]] pattern when it is associated with [[MEN 1 syndrome]]. | ||
*Genes involved in the pathogenesis of insulinoma include | *Genes involved in the pathogenesis of insulinoma include [[MEN1]] gene. [[Loss of heterozygosity]] of [[MEN1]] gene takes place on [[Chromosome 11 (human)|chromosome 11]]<nowiki/>q13. <ref name="pmid20146582">{{cite journal |vauthors=Shin JJ, Gorden P, Libutti SK |title=Insulinoma: pathophysiology, localization and management |journal=Future Oncol |volume=6 |issue=2 |pages=229–37 |year=2010 |pmid=20146582 |pmc=3498768 |doi=10.2217/fon.09.165 |url=}}</ref> | ||
==Associated Conditions== | ==Associated Conditions== | ||
* Other [[pancreatic neuroendocrine tumor]]<nowiki/>s like [[gastrinoma]], [[glucagonoma]], [[VIPoma]], [[somatostatinoma]] | * Other [[pancreatic neuroendocrine tumor]]<nowiki/>s like [[gastrinoma]], [[glucagonoma]], [[VIPoma]], [[somatostatinoma]] | ||
* [[MEN 1 syndrome|MEN 1]] <ref name="pmid1677058">{{cite journal| author=Service FJ, McMahon MM, O'Brien PC, Ballard DJ| title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. | journal=Mayo Clin Proc | year= 1991 | volume= 66 | issue= 7 | pages= 711-9 | pmid=1677058 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677058 }} </ref> | * [[MEN 1 syndrome|MEN 1]] <ref name="pmid1677058">{{cite journal| author=Service FJ, McMahon MM, O'Brien PC, Ballard DJ| title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. | journal=Mayo Clin Proc | year= 1991 | volume= 66 | issue= 7 | pages= 711-9 | pmid=1677058 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677058 }} </ref> | ||
* [[Von Hippel-Lindau Disease| | * [[Von Hippel-Lindau Disease|Von Hippel-Lindau]] | ||
* [[Neurofibromatosis type I|Neurofibromatosis type 1]] | * [[Neurofibromatosis type I|Neurofibromatosis type 1]] | ||
==Gross Pathology== | ==Gross Pathology== | ||
* On gross pathology insulinomas have a gray to red brown appearance, encapsulated <ref>{{cite book | last = Lloyd | first = Ricardo | title = Endocrine pathology : differential diagnosis and molecular advances | publisher = Springer | location = New York London | year = 2010 | isbn = 978-1441910684 }}</ref>and are usually small and solitary tumors. Although there is a case report of a large ( | * On gross pathology insulinomas have a gray to red brown appearance, encapsulated <ref>{{cite book | last = Lloyd | first = Ricardo | title = Endocrine pathology : differential diagnosis and molecular advances | publisher = Springer | location = New York London | year = 2010 | isbn = 978-1441910684 }}</ref> and are usually small and solitary tumors. Although there is a case report of a large (9 cm), [[pedunculated]] and weighing more than 100 g.<ref name="pmid15522939">{{cite journal| author=Mittendorf EA, Liu YC, McHenry CR| title=Giant insulinoma: case report and review of the literature. | journal=J Clin Endocrinol Metab | year= 2005 | volume= 90 | issue= 1 | pages= 575-80 | pmid=15522939 | doi=10.1210/jc.2004-0825 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15522939 }} </ref> | ||
[[Image:Insulinoma.jpg|thumb|center|250px|Insulinoma- Red brown appearance. By Edward Alabraba et al. - Pancreatic insulinoma co-existing with gastric GIST in the absence of neurofibromatosis-1. World Journal of Surgical Oncology 2009, 7:18doi:10.1186/1477-7819-7-18, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=6686376]] | [[Image:Insulinoma.jpg|thumb|center|250px|Insulinoma- Red brown appearance. By Edward Alabraba et al. - Pancreatic insulinoma co-existing with gastric GIST in the absence of neurofibromatosis-1. World Journal of Surgical Oncology 2009, 7:18doi:10.1186/1477-7819-7-18, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=6686376]] | ||
*Almost all insulinomas are present throughout the pancreas and extrapancreatic ones causing [[hypoglycemia]] are rare (<2%)<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref> | *Almost all insulinomas are present throughout the pancreas and extrapancreatic ones causing [[hypoglycemia]] are rare (<2%)<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref> | ||
*Various other findings are noted on gross pathology | *Various other findings are noted on [[gross pathology]] are: <ref name="de HerderNiederle2007">{{cite journal|last1=de Herder|first1=Wouter W.|last2=Niederle|first2=Bruno|last3=Scoazec|first3=Jean-Yves|last4=Pauwels|first4=Stanislas|last5=Klöppel|first5=Günter|last6=Falconi|first6=Massimo|last7=Kwekkeboom|first7=Dik J.|last8=Öberg|first8=Kjel|last9=Eriksson|first9=Barbro|last10=Wiedenmann|first10=Bertram|last11=Rindi|first11=Guido|last12=O’Toole|first12=Dermot|last13=Ferone|first13=Diego|title=Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma|journal=Neuroendocrinology|volume=84|issue=3|year=2007|pages=183–188|issn=0028-3835|doi=10.1159/000098010}}</ref> | ||
** Size of the tumor | ** Size of the tumor | ||
** Metastasis to [[lymph nodes]] | ** [[Metastasis]] to [[lymph nodes]] | ||
** Extrapancreatic involvement | ** Extrapancreatic involvement | ||
** Distant [[metastasis]] | ** Distant [[metastasis]] | ||
==Microscopic Pathology== | ==Microscopic Pathology== | ||
*On microscopic [[histopathological]] analysis, patterns like trabecular, gyriform, [[lobular]] and solid structures particularly with [[amyloid]] in fibrovascular [[stroma]] are characteristic findings of insulinoma.<ref>{{cite book | last = Lloyd | first = Ricardo | title = Endocrine pathology : differential diagnosis and molecular advances | publisher = Springer | location = New York London | year = 2010 | isbn = 978-1441910684 }}</ref> | *On microscopic [[histopathological]] analysis, patterns like trabecular, gyriform, [[lobular]] and solid structures particularly with [[amyloid]] in fibrovascular [[stroma]] are characteristic findings of insulinoma. <ref>{{cite book | last = Lloyd | first = Ricardo | title = Endocrine pathology : differential diagnosis and molecular advances | publisher = Springer | location = New York London | year = 2010 | isbn = 978-1441910684 }}</ref> | ||
*It is also evaluated for the [[mitotic index]] ([[mitosis]] per 10 high power field) and [[immunohistochemistry]] staining by [[Chromogranin A| | *It is also evaluated for the [[mitotic index]] ([[mitosis]] per 10 high power field) and [[immunohistochemistry]] staining by [[Chromogranin A|chromogranin]] A, [[synaptophysin]], and [[Ki-67]] index.<ref name="de HerderNiederle2007">{{cite journal|last1=de Herder|first1=Wouter W.|last2=Niederle|first2=Bruno|last3=Scoazec|first3=Jean-Yves|last4=Pauwels|first4=Stanislas|last5=Klöppel|first5=Günter|last6=Falconi|first6=Massimo|last7=Kwekkeboom|first7=Dik J.|last8=Öberg|first8=Kjel|last9=Eriksson|first9=Barbro|last10=Wiedenmann|first10=Bertram|last11=Rindi|first11=Guido|last12=O’Toole|first12=Dermot|last13=Ferone|first13=Diego|title=Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma|journal=Neuroendocrinology|volume=84|issue=3|year=2007|pages=183–188|issn=0028-3835|doi=10.1159/000098010}}</ref> | ||
* The structure of tumor cells observed under electron microscopy as: Group A | * The structure of tumor cells observed under electron microscopy as: | ||
** Group A characterized by abundant well-granulated typical [[Beta cells|β cells]] with trabecular arrangement. | |||
** Group B as scarce well-granulated typical [[Beta cells|β cells]] and a medullary arrangement. <ref name="pmid6311653">{{cite journal| author=Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H et al.| title=Functional and morphologic characterization of human insulinomas. | journal=Diabetes | year= 1983 | volume= 32 | issue= 10 | pages= 921-31 | pmid=6311653 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6311653 }} </ref> | |||
<gallery widths="250px"> | <gallery widths="250px"> | ||
Revision as of 13:37, 22 September 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma pathophysiology On the Web |
|
American Roentgen Ray Society Images of Insulinoma pathophysiology |
|
Risk calculators and risk factors for Insulinoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Insulinoma arises from β islet cells, which are endocrine cells that are normally involved in the production of insulin. It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Inhibitors of mTOR (rapamycin) or dual PI3K/mTOR (NVP-BEZ2235) thus have become new drugs for treating insulinoma. YY1 gene is mutated by T372R mutation that causes a defect in mitochondrial function for glucose stimulated insulin action which is thought to be involved in mTOR pathway. The progression to hypoglycemia is actually because of decreased glucose synthesis rather than increased use due to the direct effect of insulin on the liver. Insulinoma is transmitted in an autosomal dominant pattern when it is associated with MEN 1 syndrome. They are usually small (90%), sporadic (90%), solitary (90%) and benign (90%) tumors. On gross pathology insulinomas have a gray to red-brown appearance, encapsulated. On microscopic histopathological analysis, patterns like trabecular, gyriform, lobular and solid structures, particularly with amyloid in the fibrovascular stroma, are characteristic findings of insulinoma. It is also evaluated for the mitotic index (mitosis per 10 high power field) and immunohistochemistry staining by Chromogranin A, synaptophysin, and Ki-67 index. The structure of tumor cells observed under electron microscopy as group A characterized by abundant well-granulated typical β cells with trabecular arrangement and group B as scarce well-granulated typical β cells and a medullary arrangement.
Pathophysiology
Pathogenesis
- Insulinoma is a rare benign pancreatic neuroendocrine tumor that arises from β islet cells, which are cells that are normally involved in the production of insulin. Few insulinomas can also produce other hormones such as Serotonin, gastrin, ACTH, glucagon, and somatostatin. [1]
- They are usually small (90%), sporadic (90%), solitary (90%) and benign (90%) tumors.
- It usually occurs sporadically but 10% are found to be associated with MEN 1 syndrome.[2] Those associated with the MEN1 syndrome are usually malignant and higher recurrence rate (21% at 10 and 20 years) than in those without MEN 1 (5% at 10 and 7% at 20 years). [3]
- It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Inhibitors of mTOR (rapamycin) or dual PI3K/mTOR (NVP-BEZ2235) thus have become new drugs for treating insulinoma.
- An oral mTOR inhibitor, Everolimus, make better glycemic control in people having an insulinoma.[4] The pathway will give more possibilities for medical treatment. [5]
- Mitochondria play a key role in glucose and insulin coupling to assure insulin secretion after glucose stimulation in pancreatic β cells. Coupling is impaired due to abnormal mitochondrial function in β cells causes the death of the cell.[6] YY1 regulates this mitochondrial function.[7]
- T372R mutation increases the transcription of YY1.[8]
- The understanding of role and functions of YY1 in β cells in near future might prove to be therapeutic potentials.
- The progression to hypoglycemia is actually because of decreased glucose synthesis rather than increased use due to the direct effect of insulin on the liver.[9]
- The neuroglycopenic symptoms appear eventually due to decreased blood glucose. Hypoglycemia stimulates catecholamine release which produces adrenergic symptoms.[10]
Genetics
- Insulinoma is transmitted in an autosomal dominant pattern when it is associated with MEN 1 syndrome.
- Genes involved in the pathogenesis of insulinoma include MEN1 gene. Loss of heterozygosity of MEN1 gene takes place on chromosome 11q13. [11]
Associated Conditions
- Other pancreatic neuroendocrine tumors like gastrinoma, glucagonoma, VIPoma, somatostatinoma
- MEN 1 [3]
- Von Hippel-Lindau
- Neurofibromatosis type 1
Gross Pathology
- On gross pathology insulinomas have a gray to red brown appearance, encapsulated [12] and are usually small and solitary tumors. Although there is a case report of a large (9 cm), pedunculated and weighing more than 100 g.[13]
- Almost all insulinomas are present throughout the pancreas and extrapancreatic ones causing hypoglycemia are rare (<2%)[14]
- Various other findings are noted on gross pathology are: [15]
- Size of the tumor
- Metastasis to lymph nodes
- Extrapancreatic involvement
- Distant metastasis
Microscopic Pathology
- On microscopic histopathological analysis, patterns like trabecular, gyriform, lobular and solid structures particularly with amyloid in fibrovascular stroma are characteristic findings of insulinoma. [16]
- It is also evaluated for the mitotic index (mitosis per 10 high power field) and immunohistochemistry staining by chromogranin A, synaptophysin, and Ki-67 index.[15]
- The structure of tumor cells observed under electron microscopy as:
-
![Histopathology of pancreatic endocrine tumor (insulinoma)[18]](/images/2/2f/Pancreatic_insulinoma_histology_2.JPG)
Histopathology of pancreatic endocrine tumor (insulinoma)[18] -
![Histopathology of pancreatic endocrine tumor (insulinoma). Chromogranin A immunostain[18]](/images/a/a3/Pancreatic_insulinoma_histopathology_3.JPG)
Histopathology of pancreatic endocrine tumor (insulinoma). Chromogranin A immunostain[18] -
![Histopathology of pancreatic endocrine tumor (insulinoma). Insulin immunostain[18]](/images/d/d5/Pancreatic_insulinoma_histology_4.JPG)
Histopathology of pancreatic endocrine tumor (insulinoma). Insulin immunostain[18]
![Histopathology of pancreatic endocrine tumor (insulinoma)[18]](/index.php/File:Pancreatic_insulinoma_histology_2.JPG)
![Histopathology of pancreatic endocrine tumor (insulinoma). Chromogranin A immunostain[18]](/index.php/File:Pancreatic_insulinoma_histopathology_3.JPG)
![Histopathology of pancreatic endocrine tumor (insulinoma). Insulin immunostain[18]](/index.php/File:Pancreatic_insulinoma_histology_4.JPG)
References
- ↑ AlJadir, Saadi (2015). "Insulinoma: Literature's Review (Part 1)". Endocrinology&Metabolism International Journal. 2 (3). doi:10.15406/emij.2015.02.00025. ISSN 2473-0815.
- ↑ Callender GG, Rich TA, Perrier ND (2008). "Multiple endocrine neoplasia syndromes". Surg Clin North Am. 88 (4): 863–95, viii. doi:10.1016/j.suc.2008.05.001. PMID 18672144.
- ↑ 3.0 3.1 Service FJ, McMahon MM, O'Brien PC, Ballard DJ (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clin Proc. 66 (7): 711–9. PMID 1677058.
- ↑ Kulke MH, Bergsland EK, Yao JC (2009). "Glycemic control in patients with insulinoma treated with everolimus". N Engl J Med. 360 (2): 195–7. doi:10.1056/NEJMc0806740. PMID 19129539.
- ↑ Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L; et al. (2012). "Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis". J Surg Oncol. 106 (8): 972–80. doi:10.1002/jso.23176. PMID 22711648.
- ↑ Supale S, Li N, Brun T, Maechler P (2012). "Mitochondrial dysfunction in pancreatic β cells". Trends Endocrinol Metab. 23 (9): 477–87. doi:10.1016/j.tem.2012.06.002. PMID 22766318.
- ↑ Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P (2007). "mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex". Nature. 450 (7170): 736–40. doi:10.1038/nature06322. PMID 18046414.
- ↑ Cao, Yanan; Gao, Zhibo; Li, Lin; Jiang, Xiuli; Shan, Aijing; Cai, Jie; Peng, Ying; Li, Yanli; Jiang, Xiaohua; Huang, Xuanlin; Wang, Jiaqian; Wei, Qing; Qin, Guijun; Zhao, Jiajun; Jin, Xiaolong; Liu, Li; Li, Yingrui; Wang, Weiqing; Wang, Jun; Ning, Guang (2013). "Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1". Nature Communications. 4. doi:10.1038/ncomms3810. ISSN 2041-1723.
- ↑ Rizza, R. A.; Haymond, M. W.; Verdonk, C. A.; Mandarino, L. J.; Miles, J. M.; Service, F. J.; Gerich, J. E. (1981). "Pathogenesis of Hypoglycemia in Insulinoma Patients: Suppression of Hepatic Glucose Production by Insulin". Diabetes. 30 (5): 377–381. doi:10.2337/diab.30.5.377. ISSN 0012-1797.
- ↑ Abe T (1992). "[Letter from Alabama--Medicaid and Medicare]". Kango. 44 (2): 135–40. PMID 1305178.
- ↑ Shin JJ, Gorden P, Libutti SK (2010). "Insulinoma: pathophysiology, localization and management". Future Oncol. 6 (2): 229–37. doi:10.2217/fon.09.165. PMC 3498768. PMID 20146582.
- ↑ Lloyd, Ricardo (2010). Endocrine pathology : differential diagnosis and molecular advances. New York London: Springer. ISBN 978-1441910684.
- ↑ Mittendorf EA, Liu YC, McHenry CR (2005). "Giant insulinoma: case report and review of the literature". J Clin Endocrinol Metab. 90 (1): 575–80. doi:10.1210/jc.2004-0825. PMID 15522939.
- ↑ Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K (2013). "Diagnosis and management of insulinoma". World J. Gastroenterol. 19 (6): 829–37. doi:10.3748/wjg.v19.i6.829. PMC 3574879. PMID 23430217.
- ↑ 15.0 15.1 de Herder, Wouter W.; Niederle, Bruno; Scoazec, Jean-Yves; Pauwels, Stanislas; Klöppel, Günter; Falconi, Massimo; Kwekkeboom, Dik J.; Öberg, Kjel; Eriksson, Barbro; Wiedenmann, Bertram; Rindi, Guido; O’Toole, Dermot; Ferone, Diego (2007). "Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma". Neuroendocrinology. 84 (3): 183–188. doi:10.1159/000098010. ISSN 0028-3835.
- ↑ Lloyd, Ricardo (2010). Endocrine pathology : differential diagnosis and molecular advances. New York London: Springer. ISBN 978-1441910684.
- ↑ Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H; et al. (1983). "Functional and morphologic characterization of human insulinomas". Diabetes. 32 (10): 921–31. PMID 6311653.
- ↑ 18.0 18.1 18.2 Neuroendocrine tumour of the pancreas. Libre Pathology. http://librepathology.org/wiki/index.php/Neuroendocrine_tumour_of_the_pancreas